SLC5A2 and chronic kidney disease: SGLT2 inhibitors were not associated with a significant change in eGFR (mean difference (MD), −0.75 ml/minutes per 1.73 m2, 95% CI −1.61 to 0.10, P = .09) in type 2 diabetic patients with CKD.